New blood test could spare colon cancer patients unnecessary chemo
NCT ID NCT06654622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested a blood test that looks for tiny cancer leftovers after surgery in 175 people with stage II or III colorectal cancer. The goal was to see if the test could identify who really needs chemotherapy. If it works, it could help personalize treatment and avoid chemo for those who don't need it.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood test that helps doctors decide which patients need chemotherapy after colon cancer surgery, avoiding unnecessary treatment.
- What could go wrong
- This is an observational study, not a treatment trial. The test may not be accurate enough to change practice, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
175 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study will enroll patients with stage II-III colorectal cancer who have undergone curative surgery and require assessment for molecular residual disease to determine whether adjuvant chemotherapy is necessary.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with pathologically confirmed stage II or III colorectal cancer. 2. Patients who have undergone curative-intent surgery. 3. Patients with no evidence of distant metastasis (stage IV). 4. Patients aged 18 years or older. 5. Patients who provided written informed consent. Exclusion Criteria: 1. Patients with stage IV cancer or those receiving neoadjuvant therapy. 2. Patients with non-curative resection or requiring urgent surgery. 3. Patients with a follow-up period of fewer than 3 years. 4. Patients with severe comorbidities or who are unable to participate in follow-up assessments.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colo-rectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a platform trial match the right drug combo to each tumor?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a registry make endoscopic procedures safer and more effective?
- Can extra weight complicate colorectal surgery? a new study investigates
- A new clue in the fight against colorectal cancer recurrence?